University of Ioannina
Μελέτη αντιγόνων mage για την ανάπτυξη αντικαρκινικών εμβολίων
Abstract
dc:descriptionA peptide anticancer vaccine is a valuable tool in inducing anticancer T cell response as they can harm cancer cells without destroying normal tissues. On the other hand anticancer vaccines are well characterized and can be produced in high quantities and purity. T cells play an important role in controlling tumor growth and mediating tumor regression. Anti-cancer responses, as well as CD4 and CD8 epitopes of tumor antigens, have been detected in many patients, although these responses are not accompanied by tumor regression. On the other hand, human and animal studies have shown that the combined application of class I and class ll epitopes, derived from the same tumor antigen, promotes the quality of the immune response and generates long term immunity. MAGE antigens are cancer/testis antigens (expressed in tumors but silent in normal cells except for male germ line cells), shared by many tumors. These genes are of particular interest for cancer immunotherapy. Among the MAGE genes, MAGE 3 is one of the most frequently expressed in tumors (in 76% of metastatic melanomas). There have been various efforts to detect CTL responses to MAGE 3 and MHC-I restricted CTL epitopes have been identified. Nowadays, the improved methods of peptide synthesis have allowed a greater availability of peptides in immunochemistry. To obtain potent antigens and-or effective immunogens, synthetic peptides (epitopes) have to be conjugated to a carrier molecule, either to a protein such as bovine serum albumin, either to a synthetic carrier. A new peptide carrier has been developed in our laboratory, named Sequential Oligopeptide Carriers I and II, SOCn-I and SOCn-II. The SOCn-I carrier is constructed by the repetitive moiety Lys-Aib-Gly and the SOCn-II carrier by the repetitive tetrapeptide Aib-Lys-Aib-Gly. Both carriers adopt 3₁₀-helical conformation and the Lys-NᵋΗ₂ groups exhibit defined spatial orientations, so that the attached antigenic peptides do not interact with each other or with the carrier molecule. Thus, the structure regularity of the carrier, the absence of conformational restrictions and steric hindrances for the constructed conjugates favour an optimal antibody recognition and generate potent immunogens. CD8 epitopes derived from MAGE 3 cancer antigens were anchored to the SOCn (I,II) carrier in order to improve their antigenic/immunogenic properties. Conformational studies by circular dichroism spectroscopy (CD) suggested the occurrence of well defined structures in aqueous and miceller microenvironment. Fluoresceine was covalently coupled to the SOCn-conjugates to confirm their membrane insertion by confocal microscopy. Biological studies in PMBC cells and dendritic cells, by FACS analysis, pointed out CD8⁺ T cell activation, production ofIFN-γ (ELISA assays), whereas IL-4 was not detected. The reported findings evidence the generation of Thl cytotoxic immune response derived from the SOCn-conjugates, which may lead to the development of protective immunity in anticancer vaccines.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2008
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Dimtsoudi, Dimitra
- Δημτσούδη, Δήμητρα
Subjects
dc:subject × 22- Εμβόλια, Αντικαρκινικά
- Καρκίνος
- Επαναλαμβανόμενος ολιγοπεπτιδικός φορέας
- Μελάνωμα
- Δενδριτικά κύτταρα
- CD8 Αντιγόνα
- CD4 επίτοποι
- MAGE-3 Αντιγόνο
- SOCn φορέας
- MAGE-3 antigen
- SOCn carrier
- Anticancer vaccines
- CD8 Antigen
- CD4 epitopes
- Cancer
- IFN-γ
- CD69
- Sequential oligopeptide carriers (SOCs)
- Φυσικές Επιστήμες
- Χημεία
- Natural Sciences
- Chemical Sciences
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/20602